financetom
Business
financetom
/
Business
/
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Jan 24, 2025 4:07 AM

Jan 24 (Reuters) - Merck's ( MRK ) blockbuster drug

Keytruda and Eisai's ( ESALF ) cancer drug Lenvima, in

combination with chemotherapy, failed to improve overall

survival in patients with a type of esophageal cancer in a

late-stage trial, the companies said on Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alibaba Gr Hldgs Unusual Options Activity For July 12
Alibaba Gr Hldgs Unusual Options Activity For July 12
Jul 12, 2024
Investors with a lot of money to spend have taken a bearish stance on Alibaba Gr Hldgs . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens...
Ford Motor Shares Are Trading Higher: Here's What You Need To Know
Ford Motor Shares Are Trading Higher: Here's What You Need To Know
Jul 12, 2024
Shares of Ford Motor Company ( F ) are moving higher on Friday, potentially driven by several positive developments announced during the week. What To Know: On Thursday, the Biden-Harris administration announced nearly $2 billion in funding to support the conversion of 11 shuttered or at-risk auto manufacturing facilities across eight states into electric vehicle (EV) manufacturing sites. This initiative...
Oracle Unusual Options Activity
Oracle Unusual Options Activity
Jul 12, 2024
Deep-pocketed investors have adopted a bearish approach towards Oracle , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ORCL usually suggests something big is about to happen. We gleaned this information from our observations today...
IBAT launches new lithium extraction technology in Utah
IBAT launches new lithium extraction technology in Utah
Jul 12, 2024
(This July 11 story has been officially corrected to fix the companies' production run rate in a bullet and in paragraphs 1-3 and corrects royalty information in paragraph 16) By Ernest Scheyder HOUSTON (Reuters) - International Battery Metals said this week it has launched its version of a novel type of lithium filtration technology, a move that could help usher...
Copyright 2023-2026 - www.financetom.com All Rights Reserved